4AGW
| Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases | 分子名称: | 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, 3-{2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}-N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromet hyl)phenyl}benzamide, GLYCEROL, ... | 著者 | Weisberg, E, Choi, H.G, Seeliger, M, Gray, N, Griffin, J.D. | 登録日 | 2012-02-01 | 公開日 | 2012-02-15 | 最終更新日 | 2024-05-08 | 実験手法 | X-RAY DIFFRACTION (2.6 Å) | 主引用文献 | Discovery of a Small-Molecule Type II Inhibitor of Wild-Type and Gatekeeper Mutants of Bcr-Abl, Pdgfralpha, Kit, and Src Kinases: Novel Type II Inhibitor of Gatekeeper Mutants. Blood, 115, 2010
|
|
5J7S
| Crystal structure of SM1-71 bound to TAK1-TAB1 | 分子名称: | Mitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 chimera, N-{2-[(5-chloro-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propanamide | 著者 | Gurbani, D, Westover, K.D. | 登録日 | 2016-04-06 | 公開日 | 2017-02-15 | 最終更新日 | 2023-09-27 | 実験手法 | X-RAY DIFFRACTION (2.368 Å) | 主引用文献 | Structure-guided development of covalent TAK1 inhibitors. Bioorg. Med. Chem., 25, 2017
|
|
8A7I
| Crystal structure of BRD9 bromodomain in complex with compound EA-89 | 分子名称: | Bromodomain-containing protein 9, ~{N}-[1,1-bis(oxidanylidene)thian-4-yl]-7-[3-methyl-1-(piperidin-4-ylmethyl)indol-5-yl]-4-oxidanylidene-5-propyl-thieno[3,2-c]pyridine-2-carboxamide | 著者 | Faller, M, Zink, F. | 登録日 | 2022-06-21 | 公開日 | 2022-08-10 | 最終更新日 | 2024-01-31 | 実験手法 | X-RAY DIFFRACTION (1.76 Å) | 主引用文献 | BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J, 12, 2022
|
|
4CKR
| Crystal structure of the human DDR1 kinase domain in complex with DDR1-IN-1 | 分子名称: | 1,2-ETHANEDIOL, 4-[(4-ethylpiperazin-1-yl)methyl]-n-{4-methyl-3-[(2-oxo-2,3-dihydro-1h-indol-5-yl)oxy]phenyl}-3-(trifluoromethyl)benzamide, EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 | 著者 | Canning, P, Elkins, J.M, Goubin, S, Mahajan, P, Krojer, T, Newman, J.A, Dixon-Clarke, S, Chaikuad, A, von Delft, F, Arrowsmith, C.H, Edwards, A.M, Bountra, C, Bullock, A. | 登録日 | 2014-01-07 | 公開日 | 2014-01-15 | 最終更新日 | 2023-12-20 | 実験手法 | X-RAY DIFFRACTION (2.2 Å) | 主引用文献 | Discovery of a Potent and Selective Ddr1 Receptor Tyrosine Kinase Inhibitor. Acs Chem.Biol., 8, 2013
|
|
5J9L
| Crystal structure of CPT1691 bound to TAK1-TAB1 | 分子名称: | Mitogen-activated protein kinase kinase kinase 7,TGF-beta-activated kinase 1 and MAP3K7-binding protein 1, N-(4-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide | 著者 | Gurbani, D, Westover, K.D. | 登録日 | 2016-04-10 | 公開日 | 2017-02-15 | 最終更新日 | 2023-09-27 | 実験手法 | X-RAY DIFFRACTION (2.7515 Å) | 主引用文献 | Structure-guided development of covalent TAK1 inhibitors. Bioorg. Med. Chem., 25, 2017
|
|
5JK3
| Crystal structure of TL11-128 bound to TAK1-TAB1 | 分子名称: | Mitogen-activated protein kinase kinase kinase 7,TGF-beta-activated kinase 1 and MAP3K7-binding protein 1, ~{N}-[2-[5-chloranyl-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide | 著者 | Gurbani, D, Westover, K.D. | 登録日 | 2016-04-25 | 公開日 | 2017-02-15 | 最終更新日 | 2024-10-16 | 実験手法 | X-RAY DIFFRACTION (2.371 Å) | 主引用文献 | Structure-guided development of covalent TAK1 inhibitors. Bioorg. Med. Chem., 25, 2017
|
|
5J8I
| Crystal structure of TL11-113 bound to TAK1-TAB1 | 分子名称: | Mitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 chimera, N-{2-[(5-chloro-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)oxy]phenyl}prop-2-enamide | 著者 | Gurbani, D, Westover, K.D. | 登録日 | 2016-04-07 | 公開日 | 2017-02-15 | 最終更新日 | 2023-09-27 | 実験手法 | X-RAY DIFFRACTION (2.404 Å) | 主引用文献 | Structure-guided development of covalent TAK1 inhibitors. Bioorg. Med. Chem., 25, 2017
|
|
5JH6
| Crystal structure of TL10-92 bound to TAK1-TAB1 | 分子名称: | 2-[(5-chloro-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl prop-2-enoate, Mitogen-activated protein kinase kinase kinase 7,TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 | 著者 | Gurbani, D, Westover, K.D. | 登録日 | 2016-04-20 | 公開日 | 2017-02-15 | 最終更新日 | 2023-09-27 | 実験手法 | X-RAY DIFFRACTION (2.365 Å) | 主引用文献 | Structure-guided development of covalent TAK1 inhibitors. Bioorg. Med. Chem., 25, 2017
|
|
5E7R
| Crystal structure of TL10-81 bound to TAK1-TAB1 | 分子名称: | 2-chloro-N-{2-[(5-chloro-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)oxy]phenyl}acetamide, TAK1 kinase - TAB1 chimera fusion protein | 著者 | Gurbani, D, Hunter, J.C, Tan, L, Chen, Z, Westover, K.D. | 登録日 | 2015-10-13 | 公開日 | 2016-09-21 | 最終更新日 | 2024-10-16 | 実験手法 | X-RAY DIFFRACTION (2.11 Å) | 主引用文献 | Structure-guided development of covalent TAK1 inhibitors. Bioorg. Med. Chem., 25, 2017
|
|
3CS9
| Human ABL kinase in complex with nilotinib | 分子名称: | Nilotinib, Proto-oncogene tyrosine-protein kinase ABL1 | 著者 | Cowan-Jacob, S.W, Fendrich, G, Manley, P, Liebetanz, J, Fabbro, D. | 登録日 | 2008-04-09 | 公開日 | 2008-04-22 | 最終更新日 | 2024-04-03 | 実験手法 | X-RAY DIFFRACTION (2.21 Å) | 主引用文献 | Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell, 7, 2005
|
|
4L01
| |
4L00
| |